About SELAGINE Team
Pooja Bansal, MBA
Pooja Bansal, MBA is the Business Officer at SELAGINE, INC. She graduated from the FORE School of Management and subsequently joined Ernst & Young as Senior Associate - Transaction Advisor. At E&Y she was responsible for deal advisory and leading transaction advisory projects involving valuations, valuation of intangibles and financial modeling across various sectors including financial services (investment banks, banks, technology distributor, commodity exchange and retail). After 5 years at E&Y, she joined Vodafone as General Manager, Finance where she was responsible for leading financial analysis in strategic projects, investor relations and stakeholder management. She led the $500 Million commercial deal for Fibre to Home (Fixed Consumer Broadband) and Strategic Decision Matrix for choice of vendor for over US $500 Million 3G and 4G deployment. She also led the cost optimization project for supply chain management. Ms. Bansal is an entrepreneur who has started her own Art-based company. At SELAGINE, INC, Ms. Bansal will direct the strategic business plans and investment initiatives.
Christine Mun serves as the Communications Officer at SELAGINE. In this role, she sets and guides the strategy for all communications, website, and public relations messages to consistently articulate the SELAGINE mission. Christine graduated from Loyola University in Chicago with Bachelors in Biological sciences. Following graduation, she joined the Department of Ophthalmology at University of Illinois at Chicago (UIC) as Clinical Research Coordinator and led the implementation of a NEI/National Institutes of Health funded phase I/II clinical trials as well as several Industry Sponsored Trials. Christine has participated in the FDA Pre-Investigational New Drug Application (PIND) meetings to discuss the development plans for an orphan drug. She leads the organizational activities of a national-level meeting in ocular GVHD that receives funding from NEI/NIH. She has authored numerous presentations regarding pathology of eye diseases. Christine serves as the Assistant Director of the Dry Eye & ocular GVHD Clinic at UIC.
Christine Mun, BS
Corporate Strategy Advisor
Michael T. Flavin is the Corporate Strategy Advisor at SELAGINE, INC. Dr. Flavin received his B.S. degree in chemistry from Notre Dame and his Ph.D. degree in medicinal chemistry from University of Illinois at Chicago. After completing his postdoctoral fellowship at Harvard in synthetic organic chemistry, he was a Senior Research Scientist at Baxter prior to founding MediChem Life Sciences. In 2000, MediChem completed a $54M IPO with UBS as the lead underwriter. MediChem was acquired in 2002 by deCODE genetics (NASDAQ:DCGN) to build a complete “gene map to drug” business model. He is the Managing Director of Flavin Ventures, an early stage venture creation firm focused on creating, financing and developing biotechnology companies. Dr. Flavin is also Visiting Research Professor at the University of Illinois at Chicago College of Medicine. At SELAGINE, Dr. Flavin will advise regarding a variety of high-level decisions surrounding corporate structure and FDA IND and Clinical Trial strategy.
Michael T. Flavin, PhD